Samsung Biologics reaffirmed its global contract development and manufacturing organization (CDMO) leadership by operating a standalone booth for the first time at "BioJapan 2025" in Yokohama, Japan. During the event, the company held partnership meetings with 40 top global companies, including major Japanese pharmaceutical firms, and also took part in presentation sessions.
According to the company on the 10th, the booth, which operated for three days from the 8th, drew about 1,000 visitors. Marking its third appearance since first participating in 2023, Samsung Biologics showcased to visitors the world's largest production capacity of 784,000 liters (L) and its service capabilities in next-generation modalities (therapeutic approaches).
On the first day of the event, it introduced a global CDMO strategy during a presentation session. Executive Vice President James Choi, in charge of sales support, said, "Amid regulatory changes and geopolitical uncertainty, bio corporations are demanding both rapid development and stable supply," and emphasized, "Outsourcing drug development and production to external firms is not merely about reducing expense; it is a way to build a stable supply chain and recover quickly even in times of crisis."
Choi cited pre-secured production capacity, efficient technology transfer, a proven quality system and regulatory expertise, and a flexible and scalable organizational integration framework as key elements. He explained that such an integrated CDMO partnership enhances supply continuity and agility and shortens time to market for products.
As the second presenter, Executive Vice President Kevin Sharp, in charge of Sales & Operations, said, "Demand is rapidly increasing for complex modalities such as ADCs (antibody-drug conjugates) and multispecific antibodies," and noted, "Samsung Biologics provides integrated services covering all stages from early development to commercial production."
Sharp also introduced the "Samsung Organoid" platform, which tests drug candidates using organoids (organoid; organ-like models), and the finished-dose manufacturing capabilities of its ADC-dedicated production facilities. He said, "These integrated capabilities shorten development timelines and enable parallel development and close supply chain collaboration," adding, "Ultimately, our goal is to deliver next-generation biopharmaceuticals to patients with speed, quality, and reliability."
The event also unveiled a new contract manufacturing (CMO) brand, "ExellenS™." ExellenS embraces Equivalency and Speed as core values, reflecting a commitment to maintain the same quality across all production sites and supply medicines at the time customers want.
Samsung Biologics plans to enhance its global manufacturing competitiveness by pursuing the "3S strategy" of simplification, standardization, and scalability alongside the "four core values (4E)" of customer excellence, operational excellence, quality excellence, and people excellence.
Chief Executive John Lim of Samsung Biologics said, "BioJapan 2025 was an occasion where we once again proved our technological strength and reliability on site," adding, "We will continue to expand collaboration with global clients to provide high-quality biopharmaceuticals swiftly."